0
0
0
Animal Drug and Animal Generic Drug User Fee Amendments of 2023
12/15/2023, 3:55 PM
Summary of Bill HR 1418
Bill 118 hr 1418, also known as the Animal Drug and Animal Generic Drug User Fee Amendments of 2023, is a piece of legislation currently being considered by the US Congress. The bill aims to amend the Federal Food, Drug, and Cosmetic Act to reauthorize and make improvements to the Animal Drug User Fee Act (ADUFA) and the Animal Generic Drug User Fee Act (AGDUFA).
The main purpose of this bill is to ensure the safety and effectiveness of animal drugs by providing the Food and Drug Administration (FDA) with the necessary resources to review and approve new animal drugs in a timely manner. The bill also aims to enhance communication and collaboration between the FDA and stakeholders in the animal drug industry.
Some key provisions of the bill include increasing user fees for animal drug and animal generic drug applications, establishing performance goals for the FDA in reviewing these applications, and requiring the FDA to report on its progress in meeting these goals. The bill also includes provisions to improve the transparency and accountability of the FDA's regulatory processes for animal drugs. Overall, Bill 118 hr 1418 seeks to promote the development and approval of safe and effective animal drugs, while also ensuring that the FDA has the resources and tools necessary to fulfill its regulatory responsibilities in this area.
The main purpose of this bill is to ensure the safety and effectiveness of animal drugs by providing the Food and Drug Administration (FDA) with the necessary resources to review and approve new animal drugs in a timely manner. The bill also aims to enhance communication and collaboration between the FDA and stakeholders in the animal drug industry.
Some key provisions of the bill include increasing user fees for animal drug and animal generic drug applications, establishing performance goals for the FDA in reviewing these applications, and requiring the FDA to report on its progress in meeting these goals. The bill also includes provisions to improve the transparency and accountability of the FDA's regulatory processes for animal drugs. Overall, Bill 118 hr 1418 seeks to promote the development and approval of safe and effective animal drugs, while also ensuring that the FDA has the resources and tools necessary to fulfill its regulatory responsibilities in this area.
Current Status of Bill HR 1418
Bill HR 1418 is currently in the status of Bill Introduced since March 7, 2023. Bill HR 1418 was introduced during Congress 118 and was introduced to the House on March 7, 2023. Bill HR 1418's most recent activity was Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 210. as of September 20, 2023
Bipartisan Support of Bill HR 1418
Total Number of Sponsors
1Democrat Sponsors
0Republican Sponsors
1Unaffiliated Sponsors
0Total Number of Cosponsors
0Democrat Cosponsors
0Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 1418
Primary Policy Focus
HealthComments
Sponsors and Cosponsors of HR 1418
Latest Bills
Domestic ORE Act
Bill HR 7458February 19, 2026
Foster Youth Postsecondary Education Access and Success Act
Bill HR 7463February 19, 2026
LymeX Authorization Act
Bill HR 7482February 19, 2026
Air Quality Act
Bill HR 7452February 19, 2026
Connecting Communities Through Transit Planning Act of 2026
Bill HR 7298February 19, 2026
Community Health Workforce Development Act
Bill HR 7289February 19, 2026
GRAS Oversight and Transparency Act
Bill HR 7291February 19, 2026
ICE and CBP Constitutional Accountability Act
Bill HR 7297February 19, 2026
AI for Secure Networks Act
Bill HR 7294February 19, 2026
CLEAN Act
Bill HR 7453February 19, 2026
Animal Drug and Animal Generic Drug User Fee Amendments of 2023
Bill S 1844March 12, 2024
Continuing Appropriations Act, 2024 and Other Extensions Act
Bill HR 5860December 11, 2023
